MA42440B1 - Anticorps contre la sortilin qui inhibent la liason à la progranulin - Google Patents

Anticorps contre la sortilin qui inhibent la liason à la progranulin

Info

Publication number
MA42440B1
MA42440B1 MA42440A MA42440A MA42440B1 MA 42440 B1 MA42440 B1 MA 42440B1 MA 42440 A MA42440 A MA 42440A MA 42440 A MA42440 A MA 42440A MA 42440 B1 MA42440 B1 MA 42440B1
Authority
MA
Morocco
Prior art keywords
inhibit
antibodies against
progranulin
sortilin
progranulin binding
Prior art date
Application number
MA42440A
Other languages
English (en)
French (fr)
Other versions
MA42440A (fr
Inventor
Edward Van Den Brink
Paul Parren
Ibrahim John MALIK
Lars Christian BIILMANN RØNN
Jeffrey B STAVENHAGEN
Søren CHRISTENSEN
Jan Egebjerg
Arnout Gerritsen
Rob DE JONG
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of MA42440A publication Critical patent/MA42440A/fr
Publication of MA42440B1 publication Critical patent/MA42440B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA42440A 2015-07-13 2016-07-12 Anticorps contre la sortilin qui inhibent la liason à la progranulin MA42440B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
EP16739087.1A EP3322726B1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin
PCT/EP2016/066516 WO2017009327A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin

Publications (2)

Publication Number Publication Date
MA42440A MA42440A (fr) 2018-05-23
MA42440B1 true MA42440B1 (fr) 2025-05-30

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42440A MA42440B1 (fr) 2015-07-13 2016-07-12 Anticorps contre la sortilin qui inhibent la liason à la progranulin

Country Status (35)

Country Link
US (6) US10479835B2 (enExample)
EP (1) EP3322726B1 (enExample)
JP (2) JP6979397B2 (enExample)
KR (1) KR102778576B1 (enExample)
CN (3) CN114478775A (enExample)
AR (1) AR105335A1 (enExample)
AU (1) AU2016292980B2 (enExample)
BR (1) BR112018000771A2 (enExample)
CA (1) CA2989739A1 (enExample)
CL (2) CL2018000092A1 (enExample)
CO (1) CO2017012988A2 (enExample)
CR (1) CR20180002A (enExample)
DO (1) DOP2018000014A (enExample)
EA (1) EA201890038A1 (enExample)
EC (1) ECSP18002725A (enExample)
ES (1) ES3024469T3 (enExample)
GB (1) GB201512215D0 (enExample)
HR (1) HRP20250602T1 (enExample)
HU (1) HUE071424T2 (enExample)
IL (1) IL256503B (enExample)
JO (1) JO3710B1 (enExample)
MA (1) MA42440B1 (enExample)
MX (1) MX2018000506A (enExample)
NI (1) NI201800007A (enExample)
PE (1) PE20181014A1 (enExample)
PH (1) PH12018500100A1 (enExample)
PL (1) PL3322726T3 (enExample)
RS (1) RS66856B1 (enExample)
RU (1) RU2735639C2 (enExample)
SV (1) SV2018005613A (enExample)
TN (1) TN2017000534A1 (enExample)
TW (1) TWI760305B (enExample)
UA (1) UA125136C2 (enExample)
WO (1) WO2017009327A1 (enExample)
ZA (1) ZA201708613B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
IL293994A (en) * 2019-12-23 2022-08-01 Denali Therapeutics Inc Progranulin variants, compositions comprising same and uses thereof
CA3183994A1 (en) * 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991001754A1 (en) 1989-08-09 1991-02-21 Rhodes Buck A Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
MXPA01007895A (es) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人类单克隆抗体
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
EP3225251B1 (en) * 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
CN102131826B (zh) 2008-04-27 2014-07-02 H.隆德贝克有限公司 人类分拣蛋白的晶体结构及其用于鉴定分拣蛋白的配体的用途
EP2293667A4 (en) 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
US8703125B2 (en) 2008-12-19 2014-04-22 H. Lundbeck A/S Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
JP6239635B2 (ja) 2012-11-02 2017-11-29 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 血管石灰化の誘導因子であるソルチリン１
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso

Also Published As

Publication number Publication date
AR105335A1 (es) 2017-09-27
IL256503B (en) 2022-02-01
BR112018000771A2 (pt) 2018-09-25
TWI760305B (zh) 2022-04-11
US20200190188A1 (en) 2020-06-18
TW201702273A (zh) 2017-01-16
CL2018000092A1 (es) 2018-07-06
AU2016292980B2 (en) 2022-10-06
JP6979397B2 (ja) 2021-12-15
IL256503A (en) 2018-02-28
EA201890038A1 (ru) 2018-06-29
US10479835B2 (en) 2019-11-19
ES3024469T3 (en) 2025-06-04
CR20180002A (es) 2018-04-09
US10889650B2 (en) 2021-01-12
WO2017009327A1 (en) 2017-01-19
NI201800007A (es) 2018-10-18
US20250277040A1 (en) 2025-09-04
KR102778576B1 (ko) 2025-03-07
ECSP18002725A (es) 2018-03-31
CN107849135A (zh) 2018-03-27
CA2989739A1 (en) 2017-01-19
CN114478775A (zh) 2022-05-13
EP3322726B1 (en) 2025-03-12
ZA201708613B (en) 2021-03-31
RS66856B1 (sr) 2025-06-30
CL2020002468A1 (es) 2021-01-29
MA42440A (fr) 2018-05-23
US20210269524A1 (en) 2021-09-02
DOP2018000014A (es) 2018-04-15
EP3322726C0 (en) 2025-03-12
US20170267761A1 (en) 2017-09-21
PH12018500100A1 (en) 2018-07-30
KR20180030045A (ko) 2018-03-21
US11548950B2 (en) 2023-01-10
US10428147B2 (en) 2019-10-01
EP3322726A1 (en) 2018-05-23
TN2017000534A1 (en) 2019-04-12
AU2016292980A1 (en) 2018-01-18
US12331123B2 (en) 2025-06-17
RU2018100824A (ru) 2019-08-13
RU2735639C2 (ru) 2020-11-05
HRP20250602T1 (hr) 2025-07-18
HUE071424T2 (hu) 2025-08-28
JO3710B1 (ar) 2021-01-31
JP2018529635A (ja) 2018-10-11
JP2022003058A (ja) 2022-01-11
US20180305455A1 (en) 2018-10-25
MX2018000506A (es) 2018-05-11
CN114478774A (zh) 2022-05-13
PL3322726T3 (pl) 2025-06-23
RU2018100824A3 (enExample) 2020-01-17
UA125136C2 (uk) 2022-01-19
GB201512215D0 (en) 2015-08-19
SV2018005613A (es) 2018-02-23
US20230159643A1 (en) 2023-05-25
PE20181014A1 (es) 2018-06-26
CO2017012988A2 (es) 2018-05-21
HK1254356A1 (en) 2019-07-19

Similar Documents

Publication Publication Date Title
MA42440B1 (fr) Anticorps contre la sortilin qui inhibent la liason à la progranulin
MX2023007754A (es) Una composicion que comprende un anticuerpo inhibidor de masp-2 para su uso en el tratamiento de la nefropatia por inmunoglobulina a (igan) dependiente de esteroides.
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
PH12019502869A1 (en) Agents, uses and methods for treatment
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA40035A (fr) Molécules d'anticorps de pd-l1 et leurs utilisations
MA49373B1 (fr) Compositions comprenant des souches bactériennes
MY205849A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
MA52076A (fr) Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1
MA52075A (fr) Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-l1
MA39336A1 (fr) Molécules d'anticorps anti-lag-3 et leurs utilisations
MA42711B1 (fr) Méthodes de traitement d'états pathologiques associés à une activation du complément dépendant de masp-2
MA39208B1 (fr) Molécules d'anticorps anti-pd-1 et leurs utilisations
MA39300B1 (fr) Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations
EA202191311A1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта
MA39221B1 (fr) Molécules d'anticorps anti-tim-3 et leurs utilisations